Medtronic Raises Forecasts Amid Surge in Heart Device Demand
Medtronic boosts its fiscal 2027 outlook, driven by a spike in heart device demand, while investing heavily in robotics and heart-valve technology.
Medtronic has increased its fiscal 2027 revenue growth forecast, citing robust demand for heart devices utilized in complex cardiovascular procedures. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, up from its previous projection of 6.75% to 7.25%, and has raised the lower end of its adjusted per-share profit forecast to $5.94 from $5.90, maintaining the upper limit at $6.
The company's CEO, Geoff Martha, highlighted the widespread strong performance across Medtronic's business segments and the growing contributions from newer growth platforms as key factors behind the optimistic outlook. During a post-earnings call, Martha emphasized confidence in the company's strategic positioning and market opportunities.
Strategic Investments in Robotics and Heart-Valve Technology
Alongside its improved forecasts, Medtronic has announced significant investments aimed at bolstering its portfolio. The company plans to invest $80 million in Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing rights to distribute a robotic surgical device in select international markets.
These strategic moves align with Medtronic's focus on expanding into high-growth segments of the medical technology industry. Martha noted that the penetration of soft tissue robotic surgery in emerging markets is less than 1%, highlighting the potential for growth in these areas.
Strong Performance in Cardiovascular Segment
Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was significantly driven by the company's pulsed field ablation portfolio, which experienced an 88% surge as it continues to be a preferred treatment for irregular heart rhythms.
In the latest quarter, Medtronic reported an adjusted per-share profit of $1.45 on revenue of $9.76 billion, surpassing analyst estimates of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.
Thierry Pieton, Medtronic's finance chief, mentioned that the company received tariff refunds that nearly offset the duties paid during the quarter. However, these future refunds have not been factored into the revised outlook.